Photocure ASA (PHO.OL)
- Previous Close
54.40 - Open
54.90 - Bid 56.60 x 140900
- Ask 52.30 x 97900
- Day's Range
54.30 - 56.80 - 52 Week Range
40.70 - 71.90 - Volume
90,877 - Avg. Volume
81,223 - Market Cap (intraday)
1.502B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-1.24 - Earnings Date May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 23, 2013
- 1y Target Est
99.00
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
www.photocure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PHO.OL
Performance Overview: PHO.OL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHO.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHO.OL
Valuation Measures
Market Cap
1.50B
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.25
Price/Book (mrq)
3.20
Enterprise Value/Revenue
2.70
Enterprise Value/EBITDA
53.51
Financial Highlights
Profitability and Income Statement
Profit Margin
0.05%
Return on Assets (ttm)
2.43%
Return on Equity (ttm)
0.06%
Revenue (ttm)
500.66M
Net Income Avi to Common (ttm)
267k
Diluted EPS (ttm)
-1.24
Balance Sheet and Cash Flow
Total Cash (mrq)
259.5M
Total Debt/Equity (mrq)
4.06%
Levered Free Cash Flow (ttm)
-409.5k
Research Analysis: PHO.OL
Company Insights: PHO.OL
PHO.OL does not have Company Insights